ValiRx plc (LON:VAL – Get Free Report) rose 9.4% on Thursday . The company traded as high as GBX 1.34 ($0.02) and last traded at GBX 1.34 ($0.02). Approximately 990,269 shares traded hands during mid-day trading, a decline of 3% from the average daily volume of 1,018,567 shares. The stock had previously closed at GBX 1.23 ($0.02).
ValiRx Stock Performance
The firm has a market cap of £1.79 million, a PE ratio of -67.50 and a beta of 0.59. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.64 and a quick ratio of 1.27. The stock has a 50-day moving average price of GBX 2 and a 200 day moving average price of GBX 2.65.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Read More
- Five stocks we like better than ValiRx
- Options Trading – Understanding Strike Price
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- About the Markup Calculator
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Health Care Stocks Explained: Why You Might Want to Invest
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.